{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:30:02Z","timestamp":1747179002991,"version":"3.40.5"},"reference-count":35,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2024,4,2]]},"DOI":"10.1080\/14740338.2024.2327509","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T09:31:31Z","timestamp":1710408691000},"page":"527-537","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2758-5948","authenticated-orcid":false,"given":"Michael","family":"Merz","sequence":"first","affiliation":[{"name":"Michael Merz Consulting, Freiburg, Germany"},{"name":"Mechanistic Safety, Patient Safety and Pharmacovigilance, Global Drug Development, Novartis, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Fettiplace","sequence":"additional","affiliation":[{"name":"Fettiplace Consulting Ltd, Letchworth Garden City, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Marcinak","sequence":"additional","affiliation":[{"name":"Medical Safety Evaluation, Pharmacovigilance and Patient Safety, AbbVie, North Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans L.","family":"Tillmann","sequence":"additional","affiliation":[{"name":"Division Gastroenterology, Hepatology &amp; Nutrition, Department of Medicine, East Carolina University, Greenville, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don C.","family":"Rockey","sequence":"additional","affiliation":[{"name":"Digestive Disease Research Center, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd A.","family":"Kullak-Ublick","sequence":"additional","affiliation":[{"name":"Mechanistic Safety, Patient Safety and Pharmacovigilance, Global Drug Development, Novartis, Basel, Switzerland"},{"name":"Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.045"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200502000-00002"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra021844"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2013.07.001"},{"key":"e_1_3_7_6_1","unstructured":"U.S. Department of health and human services FDA Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Guidance For Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009 [cited 2022 Jan 20]. Available from: https:\/\/www.fda.gov\/media\/116737\/download"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2017.06.003"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1194824"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.5858\/2004-128-1418-RODIHM"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70029-4"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24915"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0186-3"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1190831"},{"issue":"2","key":"e_1_3_7_14_1","first-page":"95","article-title":"The value of liver function tests in hepatocellular carcinoma","volume":"18","author":"Lopez JB","year":"1996","unstructured":"Lopez JB, Balasegaram M, Thambyrajah V, et al. The value of liver function tests in hepatocellular carcinoma. Malays J Pathol. 1996;18(2):95\u201399.","journal-title":"Malays J Pathol"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2019.11.012"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1603747"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2016.03.019"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3757"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102514"},{"key":"e_1_3_7_20_1","unstructured":"Council for international organizations of medical sciences (CIOMS) CIOMS working group on drug-induced liver injury (DILI): consensus report. Geneva; 2020 [cited 2022 Jun 28]. Available from: https:\/\/cioms.ch\/publications\/product\/drug-induced-liver-injury\/"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx158"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/381446"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.58"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.36061"},{"key":"e_1_3_7_25_1","unstructured":"National Cancer Institute Division of Cancer Treatment and Diagnosis. Common terminology criteria for adverse events (CTCAE). [cited 2022 Jul 12]. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.10.010"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15153"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15579"},{"key":"e_1_3_7_29_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40264-020-01014-2","article-title":"Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in adults with chronic viral hepatitis and adults with cirrhosis secondary to hepatitis B, C and Nonalcoholic Steatohepatitis","volume":"44","author":"Treem WR","year":"2020","unstructured":"Treem WR, Palmer M, Lonjon-Domanec I et al. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in adults with chronic viral hepatitis and adults with cirrhosis secondary to hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf. 2020;44:133\u2013165","journal-title":"Drug Saf"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.18642\/jmsaa_7100122234"},{"key":"e_1_3_7_31_1","first-page":"307","volume-title":"Comparison of Mathematics and Physics Education II. MINTUS \u2013 Beitr\u00e4ge zur mathematisch-naturwissenschaftlichen Bildung","author":"Dilling FS","year":"2022","unstructured":"Dilling FS, Stricker I. Comparison: light rays and the intercept theorem in mathematics and physics education, In: Dilling FK, editor. Comparison of Mathematics and Physics Education II. MINTUS \u2013 Beitr\u00e4ge zur mathematisch-naturwissenschaftlichen Bildung. Wiesbaden:Springer Spektrum; 2022. p. 307\u2013329."},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/s18030895"},{"key":"e_1_3_7_33_1","first-page":"84","volume-title":"Teaching and learning geometry","author":"French D","year":"2004","unstructured":"French D. The intercept theorem. In: French D, editor. Teaching and learning geometry. London (NY):Continuum International Publishing Group; 2004. p. 84\u201387."},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0014-7"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01862.x"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2655"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2024.2327509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T06:43:48Z","timestamp":1712299428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2024.2327509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,2]]}},"alternative-id":["10.1080\/14740338.2024.2327509"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2024.2327509","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"type":"print","value":"1474-0338"},{"type":"electronic","value":"1744-764X"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}